NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, announced that it has entered into a partnership to develop NFL-101, the company’s drug candidate for smoking cessation, for the Indian market with Themis Medicare Ltd (NSE – Symbol: THEMISMED; BSE - Script code: 530199) a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available to patients.

Ignacio Faus, CEO of NFL Biosciences said: “We are very happy to partner NFL-101with Themis Medicare. This is our first partnership with respect to the NFL-101 international development and we intend to implement further ones in the future, in developed as well as low and medium income countries. For this transaction, our strategic advisors are Aagami Inc., USA.”.

Link to the full press release: https://www.nflbiosciences.com/_files/ugd/d7bc94_e021f0c49b84458ba6b62c041675564c.pdf